Inventor · disambiguated record
Hyam I. Levitsky
Also filed as: LEVITSKY HYAM · LEVITSKY HYAM I
18 granted patents·13 pending applications·542 citations·filing 1996–2023
95Inventor score
Files withUNIV JOHNS HOPKINS MED12JUNO THERAPEUTICS INC10HOFFMANN LA ROCHE3PROKARIUM LTD3CENTURY THERAPEUTICS INC2
Top patents by PatentIndex Score
31 records- 0195US8012469B2Universal GM-CSF expressing bystander human K562 cell lineUNIV JOHNS HOPKINS MED·Filed 2008·Granted Sep 6, 2011·29 cites·17 claims
- 0294US10738278B2Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Aug 11, 2020·8 cites·21 claims
- 0394US6464973B1Universal GM-CSF expressing bystander human K562 cell lineUNIV JOHNS HOPKINS MED·Filed 1999·Granted Oct 15, 2002·96 cites·21 claims
- 0490US6033674AMethod of treating cancer with a tumor cell line having modified cytokine expressionUNIV JOHNS HOPKINS MED·Filed 1996·Granted Mar 7, 2000·83 cites·17 claims
- 0589US10786533B2Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·4 cites·24 claims
- 0689US7390483B2Universal GM-CSF expressing bystander human K562 cell lineUNIV JOHNS HOPKINS MED·Filed 2006·Granted Jun 24, 2008·9 cites·21 claims
- 0789US6350445B1Method of treating cancer with a tumor cell line having modified cytokine expressionUNIV JOHNS HOPKINS MED·Filed 1999·Granted Feb 26, 2002·78 cites·17 claims
- 0889US5985290APurified pancreatic tumor cell lines and related compositions and methodUNIV JOHNS HOPKINS MED·Filed 1998·Granted Nov 16, 1999·69 cites·17 claims
- 0987US5861159AControlled release of pharmaceutically active substances for immunotherapyUNIV JOHNS HOPKINS MED·Filed 1996·Granted Jan 19, 1999·94 cites·13 claims
- 1086US11529378B2Cancer therapyPROKARIUM LTD·Filed 2021·Granted Dec 20, 2022·2 cites·15 claims
- 1184US8383096B2Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccineUNIV JOHNS HOPKINS MED·Filed 2010·Granted Feb 26, 2013·5 cites·11 claims
- 1278US7740871B2Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccineUNIV JOHNS HOPKINS MED·Filed 2003·Granted Jun 22, 2010·6 cites·18 claims
- 1378US6193970B1Controlled release of pharmaceutically active substances for immunotherapyUNIV JOHNS HOPKINS MED·Filed 1998·Granted Feb 27, 2001·58 cites·27 claims
- 1475US12214001B2Cancer therapyPROKARIUM LTD·Filed 2022·Granted Feb 4, 2025·0 cites·20 claims
- 1573US12121551B2Cancer therapyPROKARIUM LTD·Filed 2022·Granted Oct 22, 2024·0 cites·11 claims
- 1663US2025360210A1Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereofCENTURY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1760US2020384031A1Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1860US2020318070A1Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1956US2023381317A1Methods for controlled activation and/or expansion of genetically engineered cells using polyethylene glycol (peg) receptorsCENTURY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2056US2011287058A1Universal GM-CSF Expressing Bystander Human Cell LineLEVITSKY HYAM I·Filed 2011·Application pending·0 cites
- 2153US2020095313A1Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2252US11793833B2Engineered B cells and related compositions and methodsJUNO THERAPEUTICS INC·Filed 2017·Granted Oct 24, 2023·0 cites·41 claims
- 2352US2002037282A1Universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and useUNIV JOHNS HOPKINS MED·Filed 2001·Application pending·0 cites
- 2448US2018051077A1Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 2545US2022225597A1Mouse model for assessing toxicities associated with immunotherapiesJUNO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2643US2019292246A1Combination therapy of a cell based therapy and a microglia imhibitorJUNO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2743US2023190796A1Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methodsJUNO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2842US11896615B2Immunotherapy methods and compositions involving tryptophan metabolic pathway modulatorsJUNO THERAPEUTICS INC·Filed 2017·Granted Feb 13, 2024·0 cites·22 claims
- 2942US2016045597A1Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 3038US2020292526A1Methods of identifying cellular attributes related to outcomes associated with cell therapyJUNO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3135US6087174AGrowth medium for primary pancreatic tumor cell cultureUNIV JOHNS HOPKINS MED·Filed 1998·Granted Jul 11, 2000·1 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when Hyam I. Levitsky files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →